CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 2,165 enrolled
Drug / intervention
Saxagliptindrug
Likely dose
Saxagliptin 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01608724
NCT01608724Phase 4Completed
CompareCT.gov

A Multicenter, Single Arm, Cohort Study to Evaluate the Efficacy and Safety of Saxagliptin 5mg, Once Daily for 24 Weeks, in Patients With Type 2 Diabetes Mellitus

AstraZeneca·interventional·Posted May 31, 2012·Updated Feb 2, 2016

In Brief

A Phase 4 clinical trial evaluating Saxagliptin for Diabetes Mellitus, Non-Insulin-Dependent. Completed, enrolled 2,165 participants across 37 sites.

Detailed Summary

The efficacy and safety study of saxagliptin 5mg, once daily for 24 weeks in patients with type 2 diabetes mellitus.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Non-Insulin-Dependent
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedMay 31, 2012
Enrollment StartNov 1, 2012
Primary CompletionMay 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.1 years ago

Interventions

Saxagliptindrug

oral, 5 mg once a day (Q.D.)